Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Genomic and Epigenomic ctDNA Profiling in Liquid Biopsies from Heavily Pretreated Patients with DNA Damage Response–Deficient Tumors

24 Jul 2025

Abstract excerpt

PURPOSE: The development of DNA damage response (DDR)-directed therapies is a major area of clinical investigation; however, to date, PARP inhibitors (PARPi) remain the only approved therapy in this space. Major challenges to DDR-targeted therapies in the post-PARPi therapy era are the context dependency of DDR alterations and the presence of preexisting resistance in this heavily pretreated population. Blood...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Genomics and Diagnostics
Share to DNA Repair Mechanisms
Share to PARP inhibition in cancer therapy

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 40705098
DOI: 10.1158/1078-0432.ccr-25-1248

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Genomic and Epigenomic ctDNA Profiling in Liquid Biopsies from Heavily Pretreated Patients with DNA Damage Response–Deficient TumorsPMID 40705098Read ↗

Comprehensive baseline ctDNA characterization in two biomarker-selected Phase 1/2 studies using genomic and methylation profilingSemantic proximity Read ↗

Molecular landscape and clinical translation of DNA damage response alterations in solid tumors: A pan-cancer perspective on precision oncology.Semantic proximity Read ↗

Utility of Homologous Recombination Deficiency Biomarkers Across Cancer TypesSemantic proximity Read ↗

Validation of genomic and transcriptomic models of homologous recombination deficiency in a real-world pan-cancer cohortSemantic proximity Read ↗

Investigation of PARP Inhibitor Resistance Based on Serially Collected Circulating Tumor DNA in Patients With BRCA -Mutated Ovarian CancerSemantic proximity Read ↗

A subset of lung cancer cases shows robust signs of homologous recombination deficiency associated genomic mutational signaturesSemantic proximity Read ↗

Integrated, Integral, and Exploratory Biomarkers in the Development of Poly(ADP-Ribose) Polymerase Inhibitors.Semantic proximity Read ↗

DirectHRD enables sensitive scar-based classification of homologous recombination deficiencySemantic proximity Read ↗

A subset of lung cancer cases shows robust signs of homologous recombination deficiency associated genomic mutational signaturesSemantic proximity Read ↗

Analysis of DNA Damage Response Gene Alterations and Tumor Mutational Burden Across 17,486 Tubular Gastrointestinal Carcinomas: Implications for TherapySemantic proximity Read ↗

<em>BRAC1</em> & <em>BRCA2</em> Methylation as a Prognostic and Predictive Biomarker in Cancer: Implementation in Liquid Biopsy in the Era of Precision MedicineSemantic proximity Read ↗

Routine Plasma-Based Genotyping to Comprehensively Detect Germline, Somatic, and Reversion BRCA Mutations among Patients with Advanced Solid Tumors.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.